On Air Now

Listen

Listen Live Now » 98.5 FM Battle Creek, Michigan

Weather

Current Conditions(Battle Creek,MI 49017)

More Weather »
60° Feels Like: 60°
Wind: WNW 8 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Showers Late 42°

Tomorrow

AM Showers 60°

Sat Night

Clear 33°

Alerts

Roche says EU panel backs lymphatic cancer drug for approval

ZURICH (Reuters) - Swiss drug company Roche said on Friday a European Union committee recommended its MabThera subcutaneous treatment for patients with non-Hodgkin lymphoma.

Roche said the opinion of the EU Committee for Medicinal Products for Human Use (CHMP) was based primarily on data from a phase III study, with a final decision from the European Commission expected in coming months.

The Commission generally follows committee recommendations, though it is not obliged to.

MabThera is a treatment for non-Hodgkin lymphoma, a cancer of the lymphatic system, and is currently delivered by an intravenous infusion which takes 2-1/2 hours to complete.

In contrast, the new MabThera subcutaneous formulation can be delivered over approximately five minutes, Roche said.

(Reporting by Alice Baghdjian)

Comments